Search Result
Results for "
oedema
" in MedChemExpress (MCE) Product Catalog:
1
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-123179
-
|
Carbonic Anhydrase
|
Cardiovascular Disease
|
Mefruside is an orally active diuretic and has a mild hypotensive effect. Mefruside inhibits the synthesis of urea in an isolated rat liver perfusion model. Mefruside can be used in studies of oedema and hypertension .
|
-
-
- HY-126179
-
-
-
- HY-B1254
-
Althiazide
|
Others
|
Cardiovascular Disease
|
Altizide (Althiazide) is an orallyactive diuretic. Altizide can be used in studies of oedema and hypertension .
|
-
-
- HY-P991416
-
|
VEGFR
|
Others
|
BAT5906 is a human monoclonal antibody (mAb) targeting VEGFA. BAT5906 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .
|
-
-
- HY-P991385
-
|
Tie
|
Neurological Disease
Metabolic Disease
|
UBX2050 is a human monoclonal antibody (mAb) targeting TIE2. UBX2050 can be used in Age-related macular degeneration, Diabetic macular oedema and Diabetic retinopathy research .
|
-
-
- HY-N10226
-
|
Prostaglandin Receptor
|
Cardiovascular Disease
Endocrinology
|
Thielavin B is an inhibitor of prostaglandin biosynthesis produced by Thielavia terricola. Thielavin B effectively influences the prostaglandin E2 synthesis from the endoperoxide. Thielavin B is significantly effective on carrageenan-induced oedema of rats when administered intravenously .
|
-
-
- HY-P991415
-
AM712
|
VEGFR
Tie
|
Others
|
ASKG-712 (AM712) is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein. ASKG-712 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .
|
-
-
- HY-126179R
-
|
Others
|
Cardiovascular Disease
Metabolic Disease
|
Fenquizone (Standard) is the analytical standard of Fenquizone. This product is intended for research and analytical applications. Fenquizone (MG-13054), a thiazide-like diuretic, exhibits chronic antihypertensive effect. Fenquizone (MG-13054) is orally acitve. Fenquizone can be used for the research of oedema and hypertension .
|
-
-
- HY-105215
-
|
Neurokinin Receptor
|
Inflammation/Immunology
|
FK888 is a potent, selective, and high affinity dipeptide NK1 receptor antagonist. FK888 displaces [3H]-SP binding with a Ki value of 0.69 nM and 0.45 microM. FK888 also inhibits SP-induced airway oedema in guinea-pig after both intravenous and oral administration .
|
-
-
- HY-15791
-
FK-3657
|
Bradykinin Receptor
|
Inflammation/Immunology
|
FR173657 is an orally active bradykinin B2 receptor antagonist (IC50: 0.56, 1.5, 2.9 nM for pig, rat, human B2 receptor respectively). FR173657 (p.o.) inhibits BK-induced bronchoconstriction in guinea-pigs (ED50: 0.075 mg/kg). FR173657 (p.o.) also inhibits Carrageenin-induced paw oedema in mice (ED50: 6.8 mg/kg). FR173657 can be used for research of inflammatory disease .
|
-
-
- HY-P5875
-
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
Inflammation/Immunology
|
P4pal10 is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 ameliorates the injury in mice myocardial ischemia/reperfusion (I/R) models .
|
-
-
- HY-14886
-
MEN16132 free base
|
Bradykinin Receptor
|
Cardiovascular Disease
Neurological Disease
|
Fasitibant chloride (MEN16132 free base) is a potent and selective nonpeptide bradykinin B2 receptor (B2R) antagonist. Fasitibant chloride reduces joint pain and diminishes joint oedema in Carrageenan-induced arthritis rat model .
|
-
-
- HY-W995241
-
|
COX
NF-κB
|
Inflammation/Immunology
|
BPD is a COX-2 and TAK1-NF-κB inhibitor, with an IC50 of 18.5 μM for COX-2. BPD inhibits the expression of iNOS, TNF-α, IL-6 and IL-1β at the transcriptional level. BPD has anti-inflammatory activity. BPD can inhibit Carrageenan-induced paw oedema and LPS-induced septic death .
|
-
-
- HY-U00153
-
-
-
- HY-111164
-
|
p38 MAPK
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
CBS-3595 is a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 with anti-inflammatory and anti-allodynic activities. CBS-3595 reduces the production of the proinflammatory cytokine IL-6 and increases the levels of the anti-inflammatory cytokine IL-10 in rats. CBS-3595 reduces paw oedema formation in the Complete Freund’s adjuvant (CFA) (HY-153808)-induced arthritis rat model. CBS-3595 is promising for research of autoimmune diseases .
|
-
-
- HY-U00153R
-
|
Drug Derivative
Reference Standards
|
Neurological Disease
|
Dixyrazine (Standard) is the analytical standard of Dixyrazine. This product is intended for research and analytical applications. Dixyrazine, a phenothiazine derivative, can prevent brain oedema induced by intracarotid injection of protamine sulphate.
|
-
-
- HY-N2196
-
|
Others
|
Inflammation/Immunology
|
Ajugasterone C is an ecdysteroid isolated from Leuzea carthamoides. Ajugasterone C shows significant inhibitory effect at 100 mg/kg dose on rat paw oedema development due to Carrageenan-induced inflammation in Sprague Dawley rats .
|
-
-
- HY-150069
-
|
Bcl-2 Family
Apoptosis
|
Metabolic Disease
|
UBX1325 is an Bcl-xL inhibitor that promotes apoptosis in senescent cells. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR) .
|
-
-
- HY-148925
-
|
Glycosidase
|
Inflammation/Immunology
|
α-Amyrenone is a triterpenoid that occurs naturally in very low concentrations in several oleoresins from Brazilian Amazon species of Protium (Burseraceae). The mixture of α and β-amyrenone inhibits α-glucosidase, and can reduce mechanical hypersensitivity and paw-oedema induced by carrageenan .
|
-
-
- HY-137920
-
|
Opioid Receptor
|
Cardiovascular Disease
|
Salvinorin A (Divinorin A) propionate is a potent, unique and short-acting high efficacy kappa-opioid receptor (KOPr) agonist with Ki value of 4.3 nm. Salvinorin A propionate is a non-nitrogenous neoclerodane isolated from Salvia divinorum .
|
-
-
- HY-100845
-
Divinorin A
|
Opioid Receptor
|
Cardiovascular Disease
|
Salvinorin A is a potent, unique and short-acting high efficacy kappa-opioid receptor (KOPr) agonist with Ki value of 4.3 nm. Salvinorin A is a non-nitrogenous neoclerodane isolated from Salvia divinorum.
|
-
-
- HY-128473
-
Valeroyl salicylate
|
COX
|
Inflammation/Immunology
|
Valeryl salicylate is a potent and irreversible cyclooxygenase-1 (COX-1) inhibitor. Valeryl salicylate shows anti-inflammatory effect .
|
-
-
- HY-N1205
-
|
Others
|
Cancer
|
Spathulenol is isolated from Aristolochia yunnanensis, and has antioxidant, anti-inflammatory, antiproliferative and antimycobacterial activities. Spathulenol shows a high antioxidant activity with an IC50 of 85.60 μg/mL in the DPPH system [1].
|
-
-
- HY-141622
-
-
-
- HY-A0235
-
Stakane
|
Others
|
Neurological Disease
|
Antrafenine (Stakane) is a non-narcotic analgesic, shows long duration of action, and excellent tolerance in pharmacological and toxicological studies .
|
-
-
- HY-W050088
-
HP 549
|
Drug Derivative
|
Neurological Disease
Inflammation/Immunology
|
Isoxepac (HP 549) is an orally active non-steroidal anti-inflammatory agent. Isoxepac can inhibit Carrageenan (HY-125474) paw oedema, adjuvant-induced polyarthritis, and prostaglandin synthesis. Isoxepac (200 mg) has an analgesic effect after meniscectomy with a low incidence of side effects. Isoxepac can be used in the research of inflammatory (rheumatoid arthritis) and pain-related diseases .
|
-
-
- HY-103025R
-
ZK 91588 (Standard); MPA (Standard)
|
Reference Standards
Glucocorticoid Receptor
|
Inflammation/Immunology
|
Methylprednisolone aceponate (Standard) is the analytical standard of Methylprednisolone aceponate. This product is intended for research and analytical applications. Methylprednisolone aceponate (ZK 91588) is a glucocorticoid and anti-inflammatory agent with weak systemic effects. Methylprednisolone aceponate is a selective glucocorticoid receptor Ligand.Methylprednisolone aceponate can be used for research of eczema and other inflammatory skin disorders .
|
-
-
- HY-103025
-
ZK 91588; MPA
|
Glucocorticoid Receptor
|
Inflammation/Immunology
|
Methylprednisolone aceponate (ZK 91588) is a glucocorticoid and anti-inflammatory agent with weak systemic effects. Methylprednisolone aceponate is a selective glucocorticoid receptor Ligand.Methylprednisolone aceponate can be used for research of eczema and other inflammatory skin disorders .
|
-
-
- HY-121678
-
POLI-67
|
Others
|
Inflammation/Immunology
|
Tetridamine ((POLI-67) ) is a non-steroidal anti-inflammatory agent and shows a marked reduction of paw swelling and pain sensibility .
|
-
-
- HY-W050088S
-
HP 549-d6
|
Isotope-Labeled Compounds
Drug Derivative
|
Neurological Disease
Inflammation/Immunology
|
Isoxepac-d6 (HP 549-d6) is the deuterium labeled Isoxepac (HY-W050088). Isoxepac (HP 549) is an orally active non-steroidal anti-inflammatory agent. Isoxepac can inhibit Carrageenan (HY-125474) paw oedema, adjuvant-induced polyarthritis, and prostaglandin synthesis. Isoxepac (200 mg) has an analgesic effect after meniscectomy with a low incidence of side effects. Isoxepac can be used in the research of inflammatory (rheumatoid arthritis) and pain-related diseases .
|
-
-
- HY-W050088R
-
HP 549 (Standard)
|
Reference Standards
Drug Derivative
|
Neurological Disease
Inflammation/Immunology
|
Isoxepac (Standard) (HP 549 (Standard)) is the analytical standard of Isoxepac (HY-W050088). This product is intended for research and analytical applications. Isoxepac (HP 549) is an orally active non-steroidal anti-inflammatory agent. Isoxepac can inhibit Carrageenan (HY-125474) paw oedema, adjuvant-induced polyarthritis, and prostaglandin synthesis. Isoxepac (200 mg) has an analgesic effect after meniscectomy with a low incidence of side effects. Isoxepac can be used in the research of inflammatory (rheumatoid arthritis) and pain-related diseases .
|
-
-
- HY-14840A
-
-
-
- HY-105172
-
CAP-232; TLN-232
|
Somatostatin Receptor
|
Inflammation/Immunology
Cancer
|
TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent .
|
-
-
- HY-P5875A
-
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
Inflammation/Immunology
|
P4pal10 TFA is the TFA salt form of P4pal10 (HY-P5875). P4pal10 TFA is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 TFA inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 TFA reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 TFA ameliorates the injury in rats myocardial ischemia/reperfusion (I/R) models .
|
-
-
- HY-110036
-
L768242
|
Cannabinoid Receptor
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
TNF Receptor
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
GW-405833 (L768242) is a potent, selective cannabinoid receptor 2 (CB2) agonist. GW405833 has EC50 and Ki values of 0.65 nM and 3.92 nM for CB2, and EC50 and Ki values of 16.1 μM and 4772 nM for CB1. GW-405833 also exhibits non-competitive CB1 antagonist, exerting its analgesic and and anti-inflammatory effect through a CB1 receptor (rather than CB2) dependent mechanism. GW-405833 can significantly inhibit the production of cAMP stimulated by Forskolin (HY-15371). GW405833 inhibits glycolysis by down-regulating HIF-1α, thereby alleviating acute liver failure (ALF) .
|
-
-
- HY-110036A
-
L768242 hydrochloride
|
Cannabinoid Receptor
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
TNF Receptor
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
GW405833 (L768242) hydrochloride is a potent, selective cannabinoid receptor 2 (CB2) agonist. GW405833 has EC50 and Ki values of 0.65 nM and 3.92 nM for CB2, and EC50 and Ki values of 16.1 μM and 4772 nM for CB1. GW405833 hydrochloride also exhibits non-competitive CB1 antagonist, exerting its analgesic effect through a CB1 receptor (rather than CB2) dependent mechanism. GW405833 hydrochloride can significantly inhibit the production of cAMP stimulated by Forskolin (HY-15371). GW405833 hydrochloride inhibits glycolysis by down-regulating HIF-1α, thereby alleviating acute liver failure (ALF) .
|
-
-
- HY-N0171A
-
β-Sitosterol (purity>98%); 22,23-Dihydrostigmasterol (purity>98%)
|
Bacterial
Apoptosis
Reactive Oxygen Species (ROS)
MDM-2/p53
Caspase
PARP
MMP
Bcl-2 Family
HIF/HIF Prolyl-Hydroxylase
TNF Receptor
Interleukin Related
NF-κB
mTOR
Lactate Dehydrogenase
CDK
Glutathione Peroxidase
SOD
|
Infection
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
Beta-Sitosterol (purity>98%) is orally active. Beta-Sitosterol exhibits multiple activities, including anti-inflammatory, anticancer, antioxidant, antimicrobial, antidiabetic, antioxidant enzyme, and analgesic. Beta-Sitosterol inhibits inflammation and impaired adipogenesis in bovine mammary epithelial cells by reducing levels of ROS, TNF-α, IL-1β, and NF-κB p65 and restoring the activity of the HIF-1α/mTOR signaling pathway. Beta-Sitosterol induces apoptosis in cancer cells through ROS-mediated mitochondrial dysregulation and p53 activation. Beta-Sitosterol exerts its anticancer effects in cancer cells by activating caspase-3, caspase-8, and caspase-9, mediating PARP inactivation, MMP loss, altered Bcl-2-Bax ratio, and cytochrome c release. Beta-Sitosterol modulates macrophage polarization and reduces rheumatoid inflammation in mice. Beta-Sitosterol inhibits tumor growth in multiple mouse cancer models. Beta-Sitosterol can be used in the research of arthritis, lung cancer, breast cancer and other cancers, diabetes, etc .
|
-
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-105172
-
CAP-232; TLN-232
|
Somatostatin Receptor
|
Inflammation/Immunology
Cancer
|
TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent .
|
-
- HY-P5875A
-
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
Inflammation/Immunology
|
P4pal10 TFA is the TFA salt form of P4pal10 (HY-P5875). P4pal10 TFA is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 TFA inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 TFA reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 TFA ameliorates the injury in rats myocardial ischemia/reperfusion (I/R) models .
|
-
- HY-P5875
-
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
Inflammation/Immunology
|
P4pal10 is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 ameliorates the injury in mice myocardial ischemia/reperfusion (I/R) models .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P991416
-
|
VEGFR
|
Others
|
BAT5906 is a human monoclonal antibody (mAb) targeting VEGFA. BAT5906 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .
|
-
- HY-P991385
-
|
Tie
|
Neurological Disease
Metabolic Disease
|
UBX2050 is a human monoclonal antibody (mAb) targeting TIE2. UBX2050 can be used in Age-related macular degeneration, Diabetic macular oedema and Diabetic retinopathy research .
|
-
- HY-P991415
-
AM712
|
VEGFR
Tie
|
Others
|
ASKG-712 (AM712) is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein. ASKG-712 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N1205
-
-
-
- HY-N0171A
-
β-Sitosterol (purity>98%); 22,23-Dihydrostigmasterol (purity>98%)
|
Cardiovascular Disease
Structural Classification
Classification of Application Fields
Leguminosae
Glycine max (L.) merr
Source classification
Plants
Inflammation/Immunology
Disease Research Fields
Steroids
|
Bacterial
Apoptosis
Reactive Oxygen Species (ROS)
MDM-2/p53
Caspase
PARP
MMP
Bcl-2 Family
HIF/HIF Prolyl-Hydroxylase
TNF Receptor
Interleukin Related
NF-κB
mTOR
Lactate Dehydrogenase
CDK
Glutathione Peroxidase
SOD
|
Beta-Sitosterol (purity>98%) is orally active. Beta-Sitosterol exhibits multiple activities, including anti-inflammatory, anticancer, antioxidant, antimicrobial, antidiabetic, antioxidant enzyme, and analgesic. Beta-Sitosterol inhibits inflammation and impaired adipogenesis in bovine mammary epithelial cells by reducing levels of ROS, TNF-α, IL-1β, and NF-κB p65 and restoring the activity of the HIF-1α/mTOR signaling pathway. Beta-Sitosterol induces apoptosis in cancer cells through ROS-mediated mitochondrial dysregulation and p53 activation. Beta-Sitosterol exerts its anticancer effects in cancer cells by activating caspase-3, caspase-8, and caspase-9, mediating PARP inactivation, MMP loss, altered Bcl-2-Bax ratio, and cytochrome c release. Beta-Sitosterol modulates macrophage polarization and reduces rheumatoid inflammation in mice. Beta-Sitosterol inhibits tumor growth in multiple mouse cancer models. Beta-Sitosterol can be used in the research of arthritis, lung cancer, breast cancer and other cancers, diabetes, etc .
|
-
-
- HY-N10226
-
-
-
- HY-N2196
-
-
-
- HY-148925
-
-
-
- HY-100845
-
-
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-W050088S
-
|
Isoxepac-d6 (HP 549-d6) is the deuterium labeled Isoxepac (HY-W050088). Isoxepac (HP 549) is an orally active non-steroidal anti-inflammatory agent. Isoxepac can inhibit Carrageenan (HY-125474) paw oedema, adjuvant-induced polyarthritis, and prostaglandin synthesis. Isoxepac (200 mg) has an analgesic effect after meniscectomy with a low incidence of side effects. Isoxepac can be used in the research of inflammatory (rheumatoid arthritis) and pain-related diseases .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: